ERBB2 and neoplasm: 131I‐NM‐02, an anti‐HER2 RT agent labelled with a β‐particle emitter, was observed to have apparent tumour uptake, rapid blood clearance and a favourable biodistribution in HER2+ tumour‐bearing mice.